Depósito Digital de Documentos de la UAB Encontrados 24 registros  anterior11 - 20siguiente  ir al registro: La búsqueda tardó 0.02 segundos. 
11.
7 p, 740.6 KB Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) / Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ; Felip, Enriqueta (Universitat Autònoma de Barcelona) ; Matito, Judit (Vall d'Hebron Institut d'Oncologia) ; Mereu, Elisabetta (Universitat Pompeu Fabra) ; Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ; Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ; Pardo Aranda, Nuria (Universitat Autònoma de Barcelona) ; Martinez de Castro, Ana (Vall d'Hebron Institut d'Oncologia) ; Remon, Jordin (Vall d'Hebron Institut d'Oncologia) ; Miquel, J. M. (Vall d'Hebron Institut d'Oncologia) ; Guillaumet-Adkins, A. (Universitat Pompeu Fabra) ; Nadal, Ernest (Institut Català d'Oncologia) ; Rodriguez Esteban, Gustavo (Universitat Pompeu Fabra) ; Arqués, O. (Stem Cells and Cancer Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Heyn, Holger (Universitat Pompeu Fabra) ; Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ; Palmer, Héctor G (Stem Cells and Cancer Group) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. [...]
2017 - 10.1093/annonc/mdx396
Annals of oncology, Vol. 28 (july 2017) , p. 2451-2457  
12.
7 p, 176.2 KB Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review / García-Foncillas, Jesús (Hospital Universitario Fundación Jiménez Díaz) ; Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Aranda, E. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Díaz-Rubio, Eduardo (Hospital Clínico San Carlos (Madrid)) ; López López, R. (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia)
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. [...]
2017 - 10.1093/annonc/mdx501
Annals of oncology, Vol. 28 (september 2017) , p. 2943-2949  
13.
9 p, 341.6 KB Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, Vincenza (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wetterskog, Daniel (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Sharabiani, M. T. A. (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ; Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Fernandez Perez, M. P. (Hospital General Universitario Morales Meseguer (Múrcia)) ; Jayaram, Anuradha (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Romanel, A. (Università di Trento. Centro di Biologia Integrata) ; Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Font Guiteras, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vazquez Estevez, S. (Hospital Universitario Lucus Augusti (Lugo)) ; González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Mellado, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Fernandez Calvo, O. (Complejo Hospitalario Universitario de Ourense) ; Méndez Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ; Durán, Ignacio (Instituto de Biomedicina de Sevilla) ; Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rodríguez Sánchez, Ángel (Hospital Universitario de León) ; Santander, C. (Hospital Universitario Miguel Servet (Saragossa)) ; Sáez, M. I. (Hospital Regional Universitario de Málaga) ; Puente, J. (Hospital Clínico San Carlos (Madrid)) ; Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wingate, Anna (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Dearnaley, David (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ; Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ; De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ; Attard, Gerhardt (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Spanish Oncology Genitourinary Group ; Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516  
14.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, Marta (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, Sara (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y. H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, Sandra (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O. M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U. M. (Cancer Research UK. Cambridge Institute) ; Jones, G. N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzmán, Marta (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, Judit (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratù, Ginevra (Cancer Genomics Group) ; Mancuso, Francesco M (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W. J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, Ana (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J. Carl (AstraZeneca (USA)) ; Caldas, Carlos (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, Jos (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M. J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
15.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Bodoky, G. (St László Hospital (Hongria)) ; García-Carbonero, Rocío (Universidad Complutense de Madrid) ; Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ; Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K. (Aichi Cancer Center Hospital) ; Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E. (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  
16.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A. X (Massachusetts General Hospital (Boston)) ; Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ; Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942  
17.
7 p, 242.6 KB Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies / Boeckx, N. (University Hospital Antwerp (Bèlgica)) ; Koukakis, R. (Biostatistics, Amgen Ltd) ; Op de Beeck, K. (University Hospital Antwerp (Bèlgica)) ; Rolfo, Christian (University Hospital Antwerp (Bèlgica)) ; Van Camp, G. (University Hospital Antwerp (Bèlgica)) ; Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Douillard, Jean-Yves (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ; André, Thierry (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ; Peeters, Marc (University Hospital Antwerp (Bèlgica))
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868  
18.
8 p, 357.7 KB Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer / Grasselli, Julieta (Institut Català d'Oncologia) ; Elez, Elena (Universitat Autònoma de Barcelona) ; Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ; Matito, Judit (Vall d'Hebron Institut d'Oncologia) ; Santos Vivas, Cristina (Institut Català d'Oncologia) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Vidal, J. (Hospital del Mar (Barcelona, Catalunya)) ; Garcia, M.. (Institut Català d'Oncologia) ; Viéitez, J. M. (Hospital Universitario Central de Asturias) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Falcó, E. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Lopez Lopez, C. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Aranda, E. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Jones, F. (Sysmex Inostics, Mundelein, USA) ; Sikri, V (Sysmex Inostics, Mundelein, USA) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Montagut, Clara (Hospital del Mar (Barcelona, Catalunya)) ; Azuara, D. (Institut Català d'Oncologia) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Salazar, R. (Institut Català d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301  
19.
9 p, 435.9 KB Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study / Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ; Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Nesbakken, A. (Oslo University Hospital (Oslo, Noruega)) ; Danielsen, S. A. (Oslo University Hospital (Oslo, Noruega)) ; Sveen, A. (Oslo University Hospital (Oslo, Noruega)) ; Buchanan, Daniel D (The University of Melbourne) ; Clendenning, M. (The University of Melbourne) ; Rosty, C. (The University of Melbourne) ; Bot, Brian M (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Milburn Jessup, J. (National Cancer Institute (Rockville, Estats Units d'Amèrica)) ; Lothe, R. A. (Oslo University Hospital (Oslo, Noruega)) ; Delorenzi, Mauro (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ; Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Sargent, D. (Mayo Clinic, Rochester, USA) ; Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031  
20.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Van Cutsem, E. (University Hospitals Leuven (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Marañón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. L. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  

Depósito Digital de Documentos de la UAB : Encontrados 24 registros   anterior11 - 20siguiente  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.